Equities

hVIVO PLC

HVO:LSE

hVIVO PLC

Health CareHealth Care Providers
  • Price (GBX)22.00
  • Today's Change-0.90 / -3.93%
  • Shares traded1.26m
  • 1 Year change21.38%
  • Beta1.1116
Data delayed at least 20 minutes, as of Nov 22 2024 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It operates through medical and scientific research services segment. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 11+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services. It offers additional clinical field trial services, such as Challenge Models, Pre-clinical, CMC & PK, Study Design & Protocol Development, Ethics & Regulatory, Phase I & II, Volunteer/Patient Recruitment, Clinical site, Monitoring, Biometrics, and Medical Writing. Its subsidiaries include hVIVO Holdings Limited, Open Orphan DAC, hVIVO Inc., and others.

  • Revenue in GBP (TTM)64.38m
  • Net income in GBP17.45m
  • Incorporated2011
  • Employees274.00
  • Location
    hVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
  • Phone+44 28 9073 7900
  • Websitehttps://hvivo.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Sareum Holdings Plc0.00-3.42m32.43m5.0032.43m5.00
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.0036.26m11.00
Poolbeg Pharma PLC0.00-4.38m38.00m8.0038.00m8.00
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Data as of Nov 22 2024. Currency figures normalised to hVIVO PLC's reporting currency: UK Pound GBX

Institutional shareholders

29.14%Per cent of shares held by top holders
HolderShares% Held
Octopus Investments Ltd.as of 04 Nov 202483.83m12.32%
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 202447.89m7.04%
Canaccord Genuity Wealth Ltd.as of 30 Apr 202427.10m3.98%
Sterling Investments Management Ltd.as of 31 Oct 20229.97m1.47%
Janus Henderson Investors UK Ltd.as of 30 Sep 20249.17m1.35%
BennBridge Ltd.as of 31 Jul 20247.42m1.09%
Liontrust Investment Partners LLPas of 30 Sep 20246.73m0.99%
Mandarine Gestion SAas of 29 Feb 20244.27m0.63%
River Global Investors LLPas of 30 Sep 2024990.44k0.15%
Lazard Asset Management LLCas of 30 Sep 2024862.12k0.13%
More ▼
Data from 31 Oct 2022 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.